HC Wainwright & Co. Maintains Buy on Axsome Therapeutics, Maintains $190 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Raghuram Selvaraju has reaffirmed a Buy rating on Axsome Therapeutics (NASDAQ:AXSM) with a maintained price target of $190.

April 02, 2024 | 12:53 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Axsome Therapeutics receives a reaffirmed Buy rating and a $190 price target from HC Wainwright & Co.
The reaffirmation of a Buy rating and a high price target by a reputable analyst firm like HC Wainwright & Co. typically signals strong confidence in the company's future performance. This can positively influence investor sentiment and potentially lead to an increase in stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100